Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RXRX
DateTimeSourceHeadlineSymbolCompany
01/17/20255:58PMPR Newswire (US)Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028NASDAQ:RXRXRecursion Pharmaceuticals Inc
01/17/20255:56PMPR Newswire (US)Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028NASDAQ:RXRXRecursion Pharmaceuticals Inc
01/17/20255:56PMPR Newswire (Canada)Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028NASDAQ:RXRXRecursion Pharmaceuticals Inc
01/17/20255:09PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/15/20254:12PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/14/20254:21PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/13/20255:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/13/20259:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/10/202510:58AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/08/202510:30AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/07/20259:15AMGlobeNewswire Inc.Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & MoreNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/06/20256:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/06/20256:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/06/20256:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/06/20258:30AMGlobeNewswire Inc.Recursion to Present at 43rd Annual JP Morgan Healthcare ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/26/20244:24PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/20/20244:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/20/20244:05PMGlobeNewswire Inc.Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/18/20246:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/17/20245:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/17/20245:05PMEdgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
12/11/20244:48PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/10/20244:56PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/09/20246:00PMGlobeNewswire Inc.Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable TolerabilityNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/06/20245:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/05/202410:29AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/04/202410:32AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/03/20244:40PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/03/20248:30AMGlobeNewswire Inc.Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and LymphomaNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/02/20247:02PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RXRX